{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T05:01:24Z","timestamp":1780722084601,"version":"3.54.1"},"reference-count":13,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.arteri.2026.500949","type":"journal-article","created":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T04:27:44Z","timestamp":1780720064000},"page":"500949","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Inclisiran for LDL-C reduction in secondary prevention: Real-world evidence from a homogeneous Spanish cohort with subgroup insights"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-1282-5416","authenticated-orcid":false,"given":"Victoria","family":"Piro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Fuente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Romano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Galv\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda del Val","family":"Groba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.arteri.2026.500949_bib0075","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arteri.2026.500949_bib0080","first-page":"2296","article-title":"Pooled patient-level analysis of inclisiran trials ORION-10 and ORION-11: a new siRNA therapeutic for LDL-C lowering","volume":"42","author":"Wright","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.arteri.2026.500949_bib0085","doi-asserted-by":"crossref","first-page":"e002184","DOI":"10.1136\/openhrt-2022-002184","article-title":"Lipid lowering with inclisiran: a real-world single-centre experience","volume":"9","author":"Padam","year":"2022","journal-title":"Open Heart"},{"key":"10.1016\/j.arteri.2026.500949_bib0090","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jacc.2024.10.106","article-title":"Real-world efficacy and safety of inclisiran: a single-country, multicenter, observational study (CHOLINET Registry)","volume":"85","author":"Gargiulo","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.arteri.2026.500949_bib0095","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/MOL.0000000000000954","article-title":"From clinical development to real-world outcomes with inclisiran","volume":"35","author":"Connolly","year":"2024","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.arteri.2026.500949_bib01301","article-title":"From clinical inertia to therapeutic optimization in patients with atherosclerotic cardiovascular disease: a Monte Carlo simulation within the ITACARE-P registry","author":"Faggiano","year":"2025","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.arteri.2026.500949_bib01401","doi-asserted-by":"crossref","DOI":"10.1177\/11795468251337425","article-title":"A real-world retrospective analysis of secondary prevention patients treated with inclisiran over 27 months","volume":"19","author":"Deaney","year":"2025","journal-title":"Clin Med Insights Cardiol"},{"key":"10.1016\/j.arteri.2026.500949_bib01201","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.arteri.2026.500949_bib0100","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s12933-021-01287-6","article-title":"Effects of evolocumab in individuals with type 2 diabetes with and without atherogenic dyslipidemia: an analysis from BANTING and BERSON","volume":"20","author":"Lorenzatti","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.arteri.2026.500949_bib0105","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","article-title":"2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD","volume":"41","author":"Cosentino","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.arteri.2026.500949_bib0110","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1016\/j.jacc.2024.03.382","article-title":"An \u201cInclisiran First\u201d strategy vs usual care in patients with atherosclerotic cardiovascular disease","volume":"83","author":"Koren","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.arteri.2026.500949_bib01251","doi-asserted-by":"crossref","first-page":"818","DOI":"10.3390\/ph18060818","article-title":"Triple non-statin therapy with ezetimibe inclisiran, and bempedoic acid in patients with genetically confirmed statin-induced rhabdomyolysis: a dual case report","volume":"18","author":"Dodul\u00edk","year":"2025","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.arteri.2026.500949_bib0115","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/9194736","article-title":"The effect of proprotein convertase subtilisin\/kexin type 9 inhibitors on nonfasting remnant cholesterol in a real world population","volume":"2018","author":"Morise","year":"2018","journal-title":"J Lipids"}],"container-title":["Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0214916826000586?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0214916826000586?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T04:27:46Z","timestamp":1780720066000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0214916826000586"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":13,"alternative-id":["S0214916826000586"],"URL":"https:\/\/doi.org\/10.1016\/j.arteri.2026.500949","relation":{},"ISSN":["0214-9168"],"issn-type":[{"value":"0214-9168","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inclisiran for LDL-C reduction in secondary prevention: Real-world evidence from a homogeneous Spanish cohort with subgroup insights","name":"articletitle","label":"Article Title"},{"value":"Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arteri.2026.500949","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Sociedad Espa\u00f1ola de Arteriosclerosis. Published by Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"500949"}}